Silexion <a href="https://laohu8.com/S/LENZ">Therapeutics</a> reports third quarter net loss of $7.5 million and cash balance of $9.2 million
Silexion Therapeutics Corp. reported a net loss of $7.5 million, or ($10.4) per share, for the nine months ended September 30, 2025, compared to a net loss of $14.8 million, or ($754.9) per share, for the same period in 2024, reflecting a 49.3% decrease. Cash and cash equivalents increased to $9.2 million as of September 30, 2025, from $1.2 million at December 31, 2024. Shareholders' equity improved to $7.0 million from a capital deficiency of $4.0 million at the end of 2024. The company completed a public offering and received proceeds from warrant exercises totaling approximately $9.5 million during the third quarter. Silexion regained full compliance with Nasdaq listing requirements in September 2025. Business developments included new preclinical data for SIL204 and preparations for Phase 2/3 clinical trial initiation in the first half of 2026, with ongoing regulatory submissions in Israel and the EU.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-25-003756), on November 12, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。